Zhao Jing, Zhao Jinyin, Zhao Xiao, Chen Weijun, Zhong Wei, Zhang Li, Li Longyun, Wang Mengzhao
Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):25-32. doi: 10.3779/j.issn.1009-3419.2013.01.05.
Epidermal growth factor receptor (EGFR) gene mutation is the most important predictor of the efficiency of EGFR-tyrosine kinase inhibitors in the treatment of non-small cell lung cancer (NSCLC). The detection of EGFR gene mutations can guide individual therapies for NSCLC. Numerous methods are used to detect EGFR gene mutation and each method has different features. This study aims to establish a real-time polymerase chain reaction (PCR) method for the detection of EGFR gene mutations using amplification refractory mutation system (ARMS) specific primers and Taqman fluorescence probes.
ARMS specific primers for the two EGFR gene mutations (E746_A750 and L858R) and Taqman fluorescence probes for the detection of the target sequence were carefully designed by the Primer Premier 5.0 software. Then, using the recombinants containing E746_A750 and L858R mutations as the study objects, we further analyzed the sensitivity and lower limit of this method, and then determined the cutoff ΔCt value to evaluate specific or non-specific amplification. A total of 100 clinical samples were collected and used to detect the EGFR gene mutations using this method.
The lower limit of this method for the detection of EGFR gene mutation was 10 copies if no interference of wild-type EGFR gene or background DNA existed. Regarding the method sensitivity, the detection resolution was as high as 1% and 0.1%-0.5% in the background of 500 and 5,000 copies/μL wild-type EGFR gene, respectively. Regarding the method specificity, non-specific amplifications were found when it was used to detect 21 L858R mutations in leukocyte DNA samples from healthy volunteers. However, the minimal ΔCt value was 14.48. Non-specific amplifications were not found when detecting 19 Del mutations. Among the 100 clinical samples, 39 mutations were detected (19 Del and 21 L858R were 21 and 18, respectively) using this method. The total mutation rate was 39.0%.
The proposed ARMS-TaqMan real-time PCR method for the detection of 19 Del and 21 L858R mutations in EGFR gene was rapid, simple, sensitive, specific, and applicable in the clinical setting.
表皮生长因子受体(EGFR)基因突变是EGFR酪氨酸激酶抑制剂治疗非小细胞肺癌(NSCLC)疗效的最重要预测指标。EGFR基因突变检测可指导NSCLC的个体化治疗。检测EGFR基因突变的方法众多,且每种方法各具特点。本研究旨在建立一种利用扩增阻滞突变系统(ARMS)特异性引物和Taqman荧光探针检测EGFR基因突变的实时聚合酶链反应(PCR)方法。
运用Primer Premier 5.0软件精心设计针对两种EGFR基因突变(E746_A750和L858R)的ARMS特异性引物以及用于检测靶序列的Taqman荧光探针。随后,以含有E746_A750和L858R突变的重组体为研究对象,进一步分析该方法的灵敏度和下限,进而确定用于评估特异性或非特异性扩增的截断ΔCt值。共收集100份临床样本,采用该方法检测EGFR基因突变。
在不存在野生型EGFR基因或背景DNA干扰的情况下,该方法检测EGFR基因突变的下限为10个拷贝。就方法灵敏度而言,在野生型EGFR基因拷贝数为500和5000拷贝/μL的背景下,检测分辨率分别高达1%和0.1% - 0.5%。就方法特异性而言,在检测健康志愿者白细胞DNA样本中的21个L858R突变时发现了非特异性扩增。然而,最小ΔCt值为14.48。检测19个缺失突变时未发现非特异性扩增。在100份临床样本中,采用该方法检测到39个突变(19个缺失突变和21个L858R突变分别为21个和18个)。总突变率为39.0%。
所提出的用于检测EGFR基因中19个缺失突变和21个L858R突变的ARMS - TaqMan实时PCR方法快速、简便、灵敏、特异,适用于临床检测。